# Dr Martens steadies global sales amid UK market challenges and strategic overhaul



Dr Martens has managed to uphold its annual guidance following a rebound in global sales, which helped counterbalance continued sluggish demand in the UK market. The iconic footwear brand reported positive momentum in its Americas direct-to-consumer business, attributed largely to strong full-price retail sales. The Asia-Pacific region also showed "good growth," particularly due to robust performance in South Korea. However, sales orders in the Europe, Middle East, and Africa (EMEA) region were described as "more variable," with the UK notably impacted by a challenging trading environment.

The company presented this update ahead of its recent annual general meeting in Camden, London, where shareholders approved all resolutions with overwhelming support. Dr Martens also revealed that its order books for the forthcoming autumn/winter season are reported to be "healthy," with demand broadly flat in the Americas and improving in the EMEA region.

Dr Martens has faced a tumultuous financial period; its annual results released earlier showed a dramatic plunge in profits, dropping over 90% to £8.8 million from £93.3 million the previous year. The steep decline was underpinned by falling turnover across key markets and increased costs related to workforce reductions and the hiring of a new chief executive officer and finance director. The company has launched a "Levers For Growth" strategy aiming to engage a wider consumer base, tap into new growth markets, and increase product purchase occasions. Progress on this strategy is expected to be detailed in the company’s forthcoming half-year results in November.

Industry analysts have noted that Dr Martens’ transition to a public company has been challenging. Dan Coatsworth, an investment analyst at AJ Bell, remarked that the firm has struggled from the outset but appears to be stabilising with its new strategy, especially in the critical US market. However, he underscored ongoing difficulties in the UK, where economic uncertainty continues to dampen demand for discretionary goods like premium footwear.

The company’s share price reflects these struggles, trading around 77.55p—down roughly 80% from its 370p initial public offering price in 2019. Since then, Dr Martens has grappled with supply chain issues and weak US demand, exacerbated by the global cost-of-living crisis that has curtailed consumer spending on higher-priced shoes.

Dr Martens’ heritage is deeply woven into multiple youth subcultures, from Mods and skinheads to punk, grunge, and Britpop. Originating in 1947 and produced in the UK since 1960, its boots initially served practical roles for postmen and police officers but evolved into a cultural icon.

Further insights reveal the complexities behind Dr Martens’ recent performance. The former CEO Kenny Wilson, who stepped down earlier this year, reflected on his tenure amid an 80% drop in share value since the IPO. He acknowledged miscalculations about the US market potential and operational challenges but highlighted significant revenue growth—from £349 million in 2018 to £877 million in 2024. Despite recent losses, Wilson emphasised the brand’s enduring global appeal and praised the resilience and adaptability shown during the COVID-19 pandemic.

Analysts also point to the company’s product strategy as an area needing refinement. Robyn Duffy, a senior consumer markets analyst, noted that an overwhelming product range might have caused consumer decision fatigue, potentially cannibalising sales and leading to flat online performance. She suggested that Dr Martens could benefit from streamlining its offerings and better balancing supply with demand.

Financially, Dr Martens has seen a 12.3% dip in turnover to £877.1 million and a 30.6% fall in operating profit to £122.2 million, with a notable reduction in dividend payouts. CEO Kenny Wilson indicated the company was entering a transitional phase, with plans to boost US demand and return to growth by fiscal year 2026 through increased marketing investment.

The firm’s new growth strategy centres on a "consumer-first" mindset, aiming to increase product purchase occasions, optimize distribution, and simplify operations. By targeting new markets and leveraging its brand strength, Dr Martens aspires to become the most desired premium footwear brand worldwide.

Investors responded positively to recent trading updates, with shares climbing up to 15% following encouraging autumn-winter sales and reduced net debt. The company also announced a £25 million annualised cost savings plan aligned with its ongoing turnaround efforts. Leadership changes are also underway, with Kenny Wilson set to step down in early 2025, succeeded by Ije Nwokorie, while Wilson remains involved until March to aid the transition.

Despite a turbulent period marked by profit warnings and market headwinds—particularly in the US and UK—Dr Martens is cautiously optimistic about significant profit growth anticipated in the coming financial year. The blend of renewed focus on consumer engagement, strategic cost management, and strong brand heritage underpins its efforts to reinvigorate the business amid a challenging global retail landscape.

### 📌 Reference Map:

* Paragraph 1 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490), [[7]](https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417)
* Paragraph 2 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490)
* Paragraph 3 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490), [[7]](https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417)
* Paragraph 4 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490), [[5]](https://www.proactiveinvestors.com/companies/news/1048730/dr-martens-sales-nosedive-british-footwear-brand-struggles-to-capture-us-market-1048730.html)
* Paragraph 5 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490), [[7]](https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417), [[2]](https://www.ft.com/content/6678d508-26a1-4296-a6b9-f05a9561526e)
* Paragraph 6 – [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490), [[3]](https://www.ft.com/content/7a5dabde-b4fe-4c01-b5a3-ffc88c67f88b)
* Paragraph 7 – [[4]](https://www.rsmuk.com/news/too-many-boots-and-not-enough-sales-hit-dr-martens-results)
* Paragraph 8 – [[5]](https://www.proactiveinvestors.com/companies/news/1048730/dr-martens-sales-nosedive-british-footwear-brand-struggles-to-capture-us-market-1048730.html), [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490)
* Paragraph 9 – [[6]](https://www.retaildive.com/news/dr-martens-shift-consumer-focused-mindset-transformation-strategy/750197/), [[7]](https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417)
* Paragraph 10 – [[2]](https://www.ft.com/content/6678d508-26a1-4296-a6b9-f05a9561526e), [[7]](https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417), [[3]](https://www.ft.com/content/7a5dabde-b4fe-4c01-b5a3-ffc88c67f88b)
* Paragraph 11 – [[2]](https://www.ft.com/content/6678d508-26a1-4296-a6b9-f05a9561526e), [[1]](https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490)

Source: [Noah Wire Services](https://www.noahwire.com)

## Bibliography

1. <https://www.dailymail.co.uk/money/markets/article-14893245/Dr-Martens-sees-global-sales-rebound-UK-demand-remains-challenging.html?ns_mchannel=rss&ns_campaign=1490&ito=1490> - Please view link - unable to able to access data
2. <https://www.ft.com/content/6678d508-26a1-4296-a6b9-f05a9561526e> - Dr Martens' shares rose by up to 15% following a positive start to the Christmas trading season, despite reporting a half-year loss. CEO Kenny Wilson stated the company is stabilising after several profit warnings and poor US performance. Revenue fell by 16% to £332.1 million, with a pre-tax loss of £27 million compared to a £25.8 million profit the previous year. Investors responded favourably to reduced net debt, lower inventory, and progress in cost savings. Sales of autumn-winter products were encouraging, and the price of the 1460 boots will remain stable next year. The company's stock has lost about 40% in value over the past year and 85% since its market debut in 2021. Permira, the UK buyout firm, floated Dr Martens during a peak in listings and has sold significant shares since then. Wilson will step down on January 6, succeeded by Ije Nwokorie, and will stay until the end of March before exploring new roles but not as a CEO.
3. <https://www.ft.com/content/7a5dabde-b4fe-4c01-b5a3-ffc88c67f88b> - Kenny Wilson, former CEO of Dr Martens, reflects on his tenure following his departure as the bootmaker saw an 80% drop in value since its 2021 IPO. Wilson, who remains the largest individual shareholder, acknowledges missteps including overestimating US market potential and operational issues in Los Angeles. Despite setbacks, he emphasises the company's revenue and profit growth from 2018 to 2024, and the brand's continued global appeal. Under his leadership, revenues grew from £349 million to £877 million and pre-tax profit surged to £93 million, though the company recently posted a £28.7 million loss. Wilson describes leading Dr Martens during the COVID-19 pandemic as a career highlight due to the team's adaptability and strong online performance. Now shifting to non-executive roles, including positions at Represent and K-Way, he intends to mentor future leaders. With decades of retail experience, starting at Levi’s and spanning roles at Claire’s and Cath Kidston, Wilson values learning and resilience. He cites his wife's health scare as a factor in stepping down, and while acknowledging challenges and accountability, remains optimistic about Dr Martens’ future and is poised to support others in leadership.
4. <https://www.rsmuk.com/news/too-many-boots-and-not-enough-sales-hit-dr-martens-results> - Robyn Duffy, senior analyst for consumer markets at RSM UK, comments on Dr Martens' poor FY24 results, noting that inventory bottlenecks in the US and weak wholesale orders in the region were expected to impact profits, compounded by inflationary cost pressures with the brand having little headroom to raise prices. She highlights strategic headwinds, including an overwhelming product selection leading to decision fatigue for consumers, potentially cannibalising sales and causing flat website sales. Duffy suggests that other successful brands have thrived by refining their product ranges and focusing on net sales, recommending that Dr Martens re-evaluate its strategy to better balance supply and demand while streamlining its product offerings to revive prospects for the brand.
5. <https://www.proactiveinvestors.com/companies/news/1048730/dr-martens-sales-nosedive-british-footwear-brand-struggles-to-capture-us-market-1048730.html> - Dr Martens PLC reported a 12.3% decrease in turnover to £877.1 million, undershooting the 11% drop forecasted by the market. Operating profit fell by 30.6% to £122.2 million, slightly better than the anticipated 34% decline. Profit after tax decreased by 46.3% to £69.2 million. CEO Kenny Wilson attributed the results to continued weak US consumer demand and announced a group-wide cost action plan intended to save up to £25 million. The total dividend was reduced from 5.84p to 2.55p. Looking ahead, Wilson warned that financial 2025 would be a transition year, with plans to drive demand in the USA to return to growth in FY26 onwards through increased marketing investment.
6. <https://www.retaildive.com/news/dr-martens-shift-consumer-focused-mindset-transformation-strategy/750197/> - Dr Martens plans to shift to a 'consumer-first' mindset after revenue fell by double digits in the latest fiscal year. The London-based footwear brand's revenue fell 10% in its 2025 fiscal year to £787.6 million. The company is instituting a new growth strategy focused on engaging more consumers, driving more product purchase occasions, curating market-right distribution, and simplifying the operating model. The strategy aims to capitalise on the company's strengths while tapping into new markets, with the goal of becoming the world's most desired premium footwear brand.
7. <https://fashionunited.com/news/business/dr-martens-announces-new-strategy-to-engage-more-consumers-as-profits-drop/2025060566417> - Heritage footwear brand Dr Martens reported a 10% year-on-year drop in overall revenues, in line with guidance, due to a 'challenging macroeconomic and consumer backdrop' in several of its core markets. In the preliminary results for the 52 weeks ended March 30, 2025, Dr Martens' group revenue dropped from £877.1 million to £787.6 million. Adjusted pre-tax profit declined to £34.1 million from £97.2 million in 2024, while profits before tax plummeted from £93 million to £8.8 million. However, the company anticipates 'significant profit growth' in the coming year (FY26) as its turnaround strategy takes shape. Dr Martens also reported a return to growth in its Americas direct-to-consumer (DTC) channel in the second half, with a marketing reset approach focusing on products and delivering £25 million in annualised cost savings.